Literature DB >> 12111878

Jointly modelling the relationship between survival and pulmonary function in cystic fibrosis patients.

Mark D Schluchter1, Michael W Konstan, Pamela B Davis.   

Abstract

Modelling the relationship between pulmonary function and survival in cystic fibrosis (CF) is complicated by the fact that measures of pulmonary function commonly used such as the forced expiratory volume in one second (FEV(1)) are measured with error, and patients with the poorest lung function are increasingly censored by death, that is, data are available only for the patients who have survived to the current age. We assume a linear random effects model for FEV1 per cent predicted, where the random intercept and slope of FEV(1) per cent predicted, along with a specified transformation of the age at death follow a trivariate normal distribution. We illustrate how this model can be used to describe the relationship between age at death and parameters of the individual patient's regression of FEV(1) per cent predicted versus age, such as the slope and the intercept or true value of FEV(1) per cent predicted at a given age. We also illustrate how the model provides empirical Bayes estimates of these individual parameters. In particular, we explore how the predicted value of the age at death might be used as a prognostic or severity index. The model and methods are illustrated on a cohort of 188 cystic fibrosis patients with a common genotype (homozygous for the DeltaF508 mutation), born on or after 1965 and followed at the CF Center at the Rainbow Babies and Children's Hospital, Cleveland, OH, U.S.A. Copyright 2002 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12111878     DOI: 10.1002/sim.1104

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  47 in total

1.  Design and powering of cystic fibrosis clinical trials using rate of FEV(1) decline as an efficacy endpoint.

Authors:  M W Konstan; J S Wagener; A Yegin; S J Millar; D J Pasta; D R VanDevanter
Journal:  J Cyst Fibros       Date:  2010-06-19       Impact factor: 5.482

Review 2.  Strategies for identifying modifier genes in cystic fibrosis.

Authors:  Michael P Boyle
Journal:  Proc Am Thorac Soc       Date:  2007-01

Review 3.  Advancing outcome measures for the new era of drug development in cystic fibrosis.

Authors:  Nicole Mayer-Hamblett; Bonnie W Ramsey; Richard A Kronmal
Journal:  Proc Am Thorac Soc       Date:  2007-08-01

4.  Year-to-year changes in lung function in individuals with cystic fibrosis.

Authors:  Theodore G Liou; Eric P Elkin; David J Pasta; Joan R Jacobs; Michael W Konstan; Wayne J Morgan; Jeffrey S Wagener
Journal:  J Cyst Fibros       Date:  2010-05-14       Impact factor: 5.482

5.  Unraveling the complex genetic model for cystic fibrosis: pleiotropic effects of modifier genes on early cystic fibrosis-related morbidities.

Authors:  Weili Li; David Soave; Melissa R Miller; Katherine Keenan; Fan Lin; Jiafen Gong; Theodore Chiang; Anne L Stephenson; Peter Durie; Johanna Rommens; Lei Sun; Lisa J Strug
Journal:  Hum Genet       Date:  2013-09-22       Impact factor: 4.132

6.  Longitudinal structural mixed models for the analysis of surgical trials with noncompliance.

Authors:  Colleen M Sitlani; Patrick J Heagerty; Emily A Blood; Tor D Tosteson
Journal:  Stat Med       Date:  2012-02-17       Impact factor: 2.373

7.  Growth Deficiency in Cystic Fibrosis Is Observable at Birth and Predictive of Early Pulmonary Function.

Authors:  Rebecca Darrah; Rebecca Nelson; Elizabeth G Damato; Michael Decker; Anne Matthews; Craig A Hodges
Journal:  Biol Res Nurs       Date:  2016-04-13       Impact factor: 2.522

8.  Complex two-gene modulation of lung disease severity in children with cystic fibrosis.

Authors:  Ruslan Dorfman; Andrew Sandford; Chelsea Taylor; Baisong Huang; Daisy Frangolias; Yongqian Wang; Richard Sang; Lilian Pereira; Lei Sun; Yves Berthiaume; Lap-Chee Tsui; Peter D Paré; Peter Durie; Mary Corey; Julian Zielenski
Journal:  J Clin Invest       Date:  2008-03       Impact factor: 14.808

9.  Interactions between secondhand smoke and genes that affect cystic fibrosis lung disease.

Authors:  J Michael Collaco; Lori Vanscoy; Lindsay Bremer; Kathryn McDougal; Scott M Blackman; Amanda Bowers; Kathleen Naughton; Jacky Jennings; Jonathan Ellen; Garry R Cutting
Journal:  JAMA       Date:  2008-01-30       Impact factor: 56.272

10.  Cystic fibrosis and lung transplantation--determination of the survival benefit.

Authors:  Clemens Aigner; Peter Jaksch; Gernot Seebacher; Samy Mazhar; Wilfried Wisser; Walter Klepetko
Journal:  Wien Klin Wochenschr       Date:  2004-05-31       Impact factor: 1.704

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.